NICE final draft guidance supports use of ranibizumab for diabetic macular oedema

Source: NICE Area: News In its Final Appraisal Determination, NICE is supporting the use of ranibizumab as an option for treating visual impairment caused by diabetic macular oedema (DMO). NICE conducted a rapid review of the original guidance, published in November 2011, because the manufacturer submitted a revised Patient Access Scheme, together with updated analyses showing the drug's superior relative effect among a sub-group of people with DMO.   The draft guidance states that ranibizumab is now recommended as an option for treating visual impairment due to diabetic macular oedema if the eye has a central retinal thickness of ?400 micrometres at the start of treatment and the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).   The closing date for appeals is 25 January 2013 and final guidance is expected to be published in February 2013.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news